Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 1228Neoplasms 1037Carcinoma, Non-Small-Cell Lung 757Prostatic Neoplasms 695Colorectal Neoplasms 597Lung Neoplasms 578Pancreatic Neoplasms 400Leukemia, Myeloid, Acute 398Neoplasm Metastasis 391Multiple Myeloma 373Ovarian Neoplasms 372Stomach Neoplasms 319Carcinoma, Hepatocellular 302Melanoma 283Brain Neoplasms 280Recurrence 278Squamous Cell Carcinoma of Head and Neck 269Head and Neck Neoplasms 239Glioblastoma 235Endometrial Neoplasms 235Triple Negative Breast Neoplasms 229Precursor Cell Lymphoblastic Leukemia-Lymphoma 225Lymphoma 225Uterine Cervical Neoplasms 224Sarcoma 202Hematologic Neoplasms 201Urinary Bladder Neoplasms 197Esophageal Neoplasms 192Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 177

Interventions

fluorodopa F 18 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Congenital Hyperinsulinism × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡